FUNCTIONAL AREAS – Page 32

OOS investigation lacks root cause during data review and approval – CAPA package with objective evidence

Identifying the initial signals of an OOS event is critical for timely and effective intervention. Symptoms may range from unexpected laboratory test results to production anomalies and equipment malfunctions. These…

Tech transfer readiness gaps during transfer to manufacturing – regulatory scrutiny implications

Identifying symptoms or signals is the first step in addressing tech transfer readiness gaps. Common signs include:Click to read the full article.

Method transfer mismatch in stability testing – how to distinguish lab error vs true failure

The first step in identifying a method transfer mismatch in stability testing is recognizing the symptoms and signals that may arise during routine testing. Symptoms could include unexpected results that…

Scale-up risk not identified during pilot scale – how to ensure smooth tech transfer

Identifying symptoms early is crucial to understanding if a scale-up risk has been overlooked during pilot production stages. Here are common signals to monitor during the pilot and initial scale-up…

Tech transfer readiness gaps during early development – downstream GMP risk and prevention

Addressing Readiness Gaps in Tech Transfer to Mitigate GMP Risks In the realm of pharmaceutical manufacturing, tech transfer during early development phases can present significant challenges. Often overlooked, these readiness…

Method development instability during transfer to manufacturing – data package improvements for filing

Recognizing early symptoms of method development instability is crucial in addressing potential compliance issues. Common signals include:Click to read the full article.

Formulation robustness underestimated during early development – regulatory scrutiny implications

Identifying symptoms of formulation robustness issues can be complex, but certain signals can be indicative of problems. These include:Click to read the full article.

Scale-up risk not identified during early development – downstream GMP risk and prevention

The first step in addressing any issue related to scale-up risks is recognizing the symptoms or signals that indicate a problem. Common symptoms may include:Click to read the full article.

Excipient variability impact during pilot scale – data package improvements for filing

Identifying symptoms of excipient variability is paramount for timely investigations. The following signals may arise during various phases of pilot-scale production:Click to read the full article.

Method development instability during early development – downstream GMP risk and prevention

Early indicators of method development instability can manifest in various ways during laboratory operations. Common symptoms include:Click to read the full article.

Method development instability during transfer to manufacturing – how to ensure smooth tech transfer

Managing Method Development Instability During Manufacturing Transition Method development instability during transfer to manufacturing can significantly disrupt operations, compromise product quality, and invite regulatory scrutiny. As pharmaceutical professionals working within…

Excipient variability impact during comparability assessment – downstream GMP risk and prevention

The first step in managing excipient variability is recognizing symptoms during manufacturing or laboratory processes. Some common signals include:Click to read the full article.